Luteolin, a naturally occurring flavonoid, induces apoptosis in various cancer cells. Little is known however concerning the underlying molecular mechanisms responsible for this activity. In this report, we reveal a novel mechanism by which luteolin-induced apoptosis occurs, and show for the first time that the apoptosis by luteolin is mediated through death receptor 5 (DR5) upregulation. Luteolin markedly induced the expression of DR5, along with Bcl-2-interacting domain cleavage and the activation of caspase-8, -10, -9 and -3. In addition, suppression of DR5 expression with siRNA efficiently reduced luteolininduced caspase activation and apoptosis. Human recombinant DR5/Fc also inhibited luteolin-induced apoptosis. On the other hand, luteolin induced neither DR5 protein expression nor apoptosis in normal human peripheral blood mononuclear cells. These results suggest that DR5 induced by luteolin plays a role in luteolin-induced apoptosis, and raises the possibility that treatment with luteolin might be promising as a new therapy against cancer.
Introduction
Luteolin is a naturally occurring flavone found in edible plants such as broccoli, celery, perilla leaf and seeds, and carrots at high concentrations (Miean and Mohamed, 2001) . The cancer preventing effect of luteolin has been examined in terms of the incidence of fibrosarcoma induced by a mutagen in mice, and was found to bring about a significant reduction in the incidence of tumors and death of mice fed luteolin-mixed diets (Elangovan et al., 1994) . A potent preventive effect via topical application of luteolin was also observed for the antitumor promotion of skin papillomas in mice (Ueda et al., 2003) . We previously reported that luteolin arrests the cell cycle in the G 1 phase in human gastric cancer cells (Matsukawa et al., 1993) . In addition, luteolin induces apoptosis in human myeloid leukemia cells (Ko et al., 2002) , where it was observed by the detection of morphologic alterations and DNA fragmentation, although it was not elucidated how luteolin caused this effect. Thus, luteolin is an important cancer chemopreventive agent that induces apoptosis in tumor cells, but little is known about the molecular and biochemical mechanisms responsible for this activity.
Death receptor 5 (DR5), also called tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2, is a member of the tumor necrosis factor-receptor (TNF-R) family (MacFarlane et al., 1997; Walczak et al., 1997) and a receptor for TNF-related apoptosis-inducing ligand (TRAIL) (Wiley et al., 1995; Pitti et al., 1996) . TRAIL selectively induces apoptosis in cancer cells in vitro and in vivo with little or no toxicity toward normal cells (Ashkenazi et al., 1999; Walczak et al., 1999; Lawrence et al., 2001) . DR5 and DR4 mediate TRAILinduced apoptosis through the formation of a deathinducing signaling complex (DISC) containing the death receptor, adapter proteins such as Fas-associated death domain (FADD), and initiator caspases such as pro-caspase-8 (Hersey and Zhang, 2001) or pro-caspase-10 ( Kischkel et al., 2001; Wang et al., 2001) . Consequently, pro-caspase-8 or pro-caspase-10 is activated by autoproteolytic processing, which then cleaves and activates downstream effector caspases, such as caspase-3. Additionally, the Bcl-2-interacting domain (Bid) is also cleaved by caspase-8 (Yamada et al., 1999) . Truncated-Bid causes the loss of mitochondrial membrane potential and caspase-9 cleavage, resulting in apoptosis. Thus, truncated-Bid is a mediator that transduces the proapoptotic signal from the extrinsic pathway to the intrinsic pathway.
DR5 is a downstream gene of the p53 tumorsuppressor gene (Wu et al., 1997; Takimoto and ElDeiry, 2000) , and inactivation of DR5 significantly increases tumor growth in vitro and in vivo (Wang and El-Deiry, 2004 ). In addition, DR5 is a specific target gene of conventional anticancer drugs such as doxorubicin and etoposide (Sheikh et al., 1998; Gibson et al., 2000; Wen et al., 2000) . Accordingly, DR5 is a specific target for effective cancer therapy.
In this study, we elucidated for the first time one of the mechanisms by which luteolin induces apoptosis in cancer cell lines, and discovered that it is a flavonoid found in edible plants that causes apoptosis through DR5-mediated apoptosis signaling. Moreover, induced apoptosis is selectively induced in cancer cells but not in normal human peripheral blood mononuclear cells (PBMC). Our results show the novel effects of luteolin and raise the possibility that it can be used as a promising strategy for the treatment of cancer.
Results

Luteolin induces apoptosis in HeLa cells
We examined the effect of luteolin on the increase of cell number in human cervical cancer HeLa cells by counting the cells. As shown in Figure 1a , the increase of cell number was suppressed by luteolin in a dosedependent manner. Figure 1b shows the morphological features of HeLa cells treated with luteolin. Luteolintreated cells exhibited characteristic features of apoptosis including chromatin condensation and nuclear fragmentation.
We showed quantitative data on luteolin-induced apoptosis (Figure 1c and d) . To investigate cell cycle behavior, logarithmically proliferating HeLa cells were incubated in the absence or presence of various concentrations of luteolin for 12, 24 or 48 h and examined by flow cytometric analysis. Treatment with luteolin increased the percentage of cells in the sub-G1 phase (Figure 1d ).
Luteolin-induced apoptosis is interrupted by the inhibition of several caspases
To determine the effectors active in luteolin-induced apoptotic pathways, we examined the role of caspases activated during apoptosis using several caspase inhibitors. As shown in Figure 2a , the pan-caspase inhibitor zVAD-fmk and caspase-3, -8 and -10 inhibitors interrupted apoptosis induced by luteolin. Specifically, caspase-10 inhibitor blocked apoptosis to the same degree as that inhibited by zVAD-fmk. In addition, caspase-9 inhibitor slightly but not significantly blocked apoptosis induced by luteolin. These data indicates that luteolin-induced apoptosis is dependent on caspases related to the extrinsic pathway.
In addition, we carried out cell counting assay using zVAD-fmk. As shown in Figure 2b , zVAD-fmk recovered the decrease of cell number by luteolin.
Luteolin induces DR5 mRNA expression and increases DR5 promoter activity in HeLa cells
Since caspase-8 and -10 inhibitors effectively inhibited apoptosis induced by luteolin, we hypothesized that death receptor pathways are involved in apoptosis. We first investigated the effects of luteolin on the expression of death receptor-related genes using an RNase protection assay. As shown in Figure 3a , luteolin significantly upregulated DR5 mRNA in HeLa cells. Caspase-8, Fas ligand, Fas, DR4, TRAIL and RIP expression was slightly increased, but DcR1 and DcR2 expression was not detected. We next carried out a Northern blot analysis to confirm the upregulation of DR5 mRNA by luteolin (Figure 3b ). Luteolin treatment increased DR5 mRNA in a dose-and time-dependent manner. Upregulation of DR5 mRNA was remarkable after 12 h with 10 mM luteolin treatment.
We then examined the effect of luteolin on DR5 promoter activity using a DR5 promoter-luciferase reporter plasmid as previously described (Yoshida et al., 2001 ) with a transient luciferase assay. As shown in Figure 3c , luteolin significantly increased DR5 promoter activity, indicating that it increases DR5 expression through the DR5 promoter in HeLa cells. The DR5-promoter plasmid we used does not contain an p53-binding site, because a functional p53-binding site is present in intron 1. Therefore, this indicates that luteolin upregulates DR5 at the transcriptional level in a p53-independent manner.
Luteolin treatments induce DR5 and DR4 protein expression, Bid cleavage and the activation of caspase-8, -10, -9 and -3
As shown in Figure 4a , we also found that luteolin increased DR5 protein expression in a dose-and timedependent manner by Western blot analysis, for which the level of protein was increased by 10 mM or more. Time course studies showed that DR5 protein started to increase 12 h after treatment with 10 mM luteolin (Figure 4a ). These band patterns for DR5 protein are consistent with the results of a previous report , and we confirmed that they could be detected by immunoblot analysis reprobed with another specific goat anti-DR5 antibody (Calbiochem, La Jolla, CA, USA) reactive toward a different epitope (data not shown). Moreover, to confirm the activation of apoptotic signals when HeLa cells were treated with the indicated concentrations of luteolin, we performed Western blot analyses of caspase-8, -10, -9 and -3 and Bid. Luteolin induced the activation of the caspases ( Figure 4b ) and Bid cleavage (Figure 4c ) at the concentration of 10 mM or more, which was correlated with the induction of DR5 protein. Next, we performed Western blot analysis of TRAIL and DR4. TRAIL expression was not markedly induced by luteolin (Figure 4d ), but luteolin slightly increased DR4 protein expression (Figure 4d ), which was correlated with the results of the RNase protection assay (Figure 3a ).
DR5 siRNA blocks apoptosis induced by luteolin
We next examined whether or not upregulation of DR5 expression by luteolin is related to its effect on apoptosis in HeLa cells. The induction of DR5 protein was efficiently reduced by transiently transfected DR5 Figure 5a ). In addition, the suppression of DR5 expression by siRNA prevented the activation of caspase-9 and -3 ( Figure 5a ), and apoptosis induced by luteolin ( Figure 5b ). These data indicates that upregulation of DR5 accounts at least in part for apoptosis caused by the luteolin treatment of HeLa cells.
At the same time, we performed an experiment using siRNA of DR4 gene to downregulate the expression of DR4. The siRNA of DR4 effectively reduced DR4 expression ( Figure 5a ), but did not suppress the luteolininduced apoptosis in HeLa cells ( Figure 5b ). Thus, the enhancement of apoptosis caused by luteolin is specifically due to DR5 but not DR4.
DR5/Fc chimera protein and anti-TRAIL antibody block apoptosis induced by luteolin
To confirm that the induction of apoptosis by luteolin is mediated through DR5, we used a human recombinant DR5/Fc chimera protein, which has dominant negative function against DR5. DR5/Fc chimera protein most effectively inhibited the luteolin-induced apoptosis at 1 mg/ml or more (data not shown), and we used DR5/Fc chimera protein at 1 mg/ml in this study. As shown in Figure 6a , DR5/Fc chimera protein partially blocked apoptosis caused by luteolin treatment. On the other hand, the chimera protein of another death receptor, TNF-R/Fc, could not block it. Moreover, in order to indicate more clearly that TRAIL is involved in luteolin-induced apoptosis, we conducted an experiment using neutralizing anti-TRAIL antibody (Figure 6b ). Anti-TRAIL antibody weakly but significantly inhibited luteolin-induced apoptosis; however, anti-EWS antibody as a control could not block luteolin-induced apoptosis. Thus, these results demonstrated that the enhancement of apoptosis caused by luteolin is at least partially mediated via the interaction between TRAIL and DR5.
Luteolin also induces DR5 expression and apoptosis in other human malignant tumor cells
We next investigated whether luteolin induces DR5 protein in other human malignant tumor cells, using DU145 prostate cancer cell line. Luteolin induced DR5 expression and apoptosis in a dose-dependent manner (Figure 7a and b) , and that suppression of DR5 expression with siRNA efficiently reduced luteolininduced apoptosis in DU145 as well as in HeLa cells (Figure 7c and d) . These observations suggest that luteolin can induce apoptosis via DR5 upregulation not only in HeLa cells but also in other human malignant tumor cells.
Luteolin does not induce DR5 protein expression and apoptosis in normal human PBMC
Since we found that luteolin upregulates DR5 expression and induces apoptosis in HeLa cells and DU145 cells, we next examined the effect of luteolin treatment on normal human cells. The side effects of chemotherapeutic agents on hematopoietic cells are a major problem during clinical treatment. Thus, we used normal human PBMC as a model. The level of DR5 expression was significantly lower in normal human PBMC compared with HeLa cells, and luteolin did not induce DR5 protein expression (Figure 8a ). Furthermore, it did not induce apoptosis in normal human PBMC (Figure 8b ). (a) HeLa cells were treated with 10 mM luteolin for 24 h with or without various inhibitors. À, DMSO only; C-3, treated with zDEVD-fmk (caspase-3 inhibitor); C-8, treated with zIETD-fmk (caspase-8 inhibitor); C-9, treated with zLEHD-fmk (caspase-9 inhibitor); C-10, treated with zAEVD-fmk (caspase-10 inhibitor); VAD, treated with zVAD-fmk (pan-caspase inhibitor). All caspase inhibitors were applied at 20 mM. Sub-G1 populations (apoptotic cells) were detected by flow cytometry as described in Materials and methods. *Po0.05 when compared to treatment with only 10 mM luteolin. (b) HeLa cells were treated with 10 mM luteolin for 24 h with or without 20 mM zVAD-fmk (pan-caspase inhibitor). Cell number was counted as described in Materials and methods. The cell number with solvents only was estimated as 100%. À, solvents only. *Po0.05. The values shown are means (n ¼ 3); bars, 7s.d.
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Discussion
Luteolin exhibits antitumor effects by inducing apoptosis (Ueda et al., 2003) . However, the molecular mechanism responsible for this has not been elucidated. In this study, we found that apoptosis induced by luteolin is mediated by the upregulation of DR5.
We showed for the first time that luteolin increases DR5 expression in HeLa cells (Figure 3a and b) . Moreover, it enhances DR5 promoter activity (Figure 3c ). The tumor-suppressor gene p53 transactivates the DR5 gene through an intronic p53-binding site (Takimoto and El-Deiry, 2000) . We used the 5 0 -flanking region of the DR5 gene without a p53-binding site for the luciferase reporter assay. In addition, HeLa cells have a functionally inactivated-p53 protein, which forms a complex with the E6 oncoprotein encoded by human papilloma viruses (May et al., 1991) . Moreover, we observed increased expression of DR5 by luteolin in DU145 cells harboring p53 mutation (Figure 7a ). These observations suggest that luteolin induces DR5 expression in human malignant tumor cells in a p53-independent manner.
Several observations suggest that luteolin enhances the apoptosis through the DR5 upregulation. (i) Caspase-8 and -10 were activated by luteolin treatment (Figure 4b ). In addition, caspase-8 and -10 inhibitors efficiently blocked luteolin-induced apoptosis (Figure 2 ). Caspase-8 and -10 are important direct downstream mediators of DR5. (ii) Bid was cleaved by luteolin treatment (Figure 4c ). Bid interconnects the extrinsic apoptotic pathway initiated by DR5 to the intrinsic apoptotic pathway (Yamada et al., 1999) , where caspase-9 is activated as a secondary effect by Bid. (iii) Luteolin upregulated DR5, and the upregulation was correlated with the induction of apoptosis (Figures 1, 3 and 4a ). In addition, the activation of mediator caspases was correlated with the upregulation of DR5 (Figures 3  and 4) . Previous reports showed that the overexpression of DR5 leads to the apoptotic death of cancer cells Inductions of apoptosis and DR5 expression by luteolin M Horinaka et al (Sheridan et al., 1997; Wu et al., 1997) . (iv) Most importantly, only the suppression of DR5 expression by siRNA blocked luteolin-induced caspase activation and -apoptosis, indicating that DR5 upregulation induced by luteolin is responsible for the induction of apoptosis in HeLa cells and DU145 cells (Figures 5 and 7) . On the other hand, the suppression of DR4 expression by siRNA could not block the luteolin-induced-apoptosis.
(v) Finally, DR5/Fc chimera protein partially blocked apoptosis induced by treatment with luteolin ( Figure 6a ). On the other hand, anti-TRAIL antibody very weakly blocked the apoptosis (Figure 6b ). Several studies have reported that death receptors such as Fas and TNF-R can induce apoptosis in a ligand-independent manner (Beltinger et al., 1999; Fumarola et al., 2001; Qiao et al., 2001) . Furthermore, DR5 is also believed to be able to induce ligand-independent apoptosis (Sheikh and Huang, 2004) . We therefore raise a possibility that luteolin might induce apoptosis through other mechanisms such as a ligand-independent manner rather than the interaction between TRAIL and DR5. For a chemotherapeutic agent, it is important to efficiently kill cancer cells but not normal cells. In particular, the damage of hematopoietic cells is a serious problem. We found that luteolin has no cytotoxicity against human normal PBMC (Figure 8 ). Luteolin treatment did not induce apoptosis in PBMC because DR5 expression was not induced by it, where the level of DR5 expression was originally very low (Figure 8a ). Some studies also reported that DR5 is more strongly expressed in cancer cells than in normal cells (Ichikawa et al., 2001; Koornstra et al., 2003) . Previous studies in vivo have shown the biological effects of luteolin, such as preventing carcinogenesis in mice (Elangovan et al., 1994; Ueda et al., 2003) . When rats were orally given luteolin, the total luteolin concentration was 15.5 mM in the blood plasma 30 min after dosing (Shimoi et al., 1998) . This humoral level of luteolin was similar to the concentration used in our study. For humans, luteolin is obtained on a daily basis through edible plants. Furthermore, luteolin can be orally or topically administrated without harm (Merfort et al., 1994; Shimoi et al., 1998) . Problems of side effects during luteolin treatment have not previously been reported. Luteolin has antimutagenic activity (Huang et al., 1983) , and conventional anticancer agents that activate the DR5 gene exhibit genotoxicity (Sheikh et al., 1998; Gibson et al., 2000; Wen et al., 2000) . Our findings imply that luteolin may be utilized as an agent that is safer than these conventional anticancer agents. Moreover, we found that luteolin selectively induces apoptosis in HeLa and DU145 cells compared with PBMC, and that this is dependent on DR5 expression in a p53-independent manner. p53 mutations are present in more than half of all malignancies (Greenblatt et al., 1994) , and mutations in the DR5 gene are rare (Pai et al., 1998; Jeng and Hsu, 2002; Dechant et al., 2004) . Taken together, this raises the possibility that luteolin might be effective against various types of malignancies associated with p53 mutations.
In summary, luteolin activates the DR5 gene through p53-independent regulation and induces apoptosis via DR5 upregulation. In addition, it does not induce DR5 protein expression and apoptosis in normal human PBMC. These results highlight a new mechanism responsible for luteolin-induced apoptosis, and raise the possibility that luteolin might be promising as a new cancer therapy.
Materials and methods
Reagents
Luteolin (Wako, Osaka, Japan) was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 0. 02% in media Inductions of apoptosis and DR5 expression by luteolin M Horinaka et al without causing cytotoxicity. Goat polyclonal neutralizing anti-human TRAIL antibody, human recombinant DR5 (TRAIL-R2)/Fc, TNF-R/Fc chimera protein, and caspase inhibitors such as zVAD-fmk, zDEVD-fmk, zIETD-fmk, zLEHD-fmk and zAEVD-fmk were purchased from R&D Systems (Minneapolis, MN, USA). Goat polyclonal anti-EWS antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Caspase inhibitors were subsequently diluted in DMSO before use.
Cell culture and cell counting assay
Human cervical cancer HeLa cells provided from Dr Y Shiio of the University of Tokyo were maintained in Dulbecco'sModified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 4 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, and incubated at 371C in a humidified atmosphere of 5% CO 2 . Human prostate cancer DU145 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, and incubated at 371C in a humidified atmosphere of 5% CO 2 . Normal human PBMC were isolated as previously described (Nakata et al., 2004) . PBMC were acquired from a healthy volunteer after obtaining informed consent. For the cell counting assay, cells were plated at a density of 4 Â 10 4 cells in 12-well dishes. At 24 h after cell plating, various concentrations of luteolin were added to the culture medium. Cells were counted 24 and 48 h after luteolin treatment. 
Analysis of apoptosis
Cells grown in six-well plates were left untreated, incubated with DMSO or with luteolin for 24 h. They were then washed in PBS, fixed in methanol, incubated with 4 0 -diamidino-2-phenylindole (DAPI) solution for 30 min in the dark, and then analyzed using a fluorescent microscope (Olympus, Tokyo, Japan) at 420 nm.
Unsynchronized cells were exposed to the agent for 12, 24 or 48 h and then harvested from the culture dishes. After washing with PBS, the cells were treated with 0.1% Triton X-100 and RNase A, and their nuclei were then stained with propidium iodide (PI) before their DNA content was measured as previously described (Nakata et al., 2004) . For each experiment, 10 000 cells were collected.
Northern blot analysis and RNase protection assay
Total RNA from HeLa cells was isolated using Sepasol-RNA I (Nacalai Tesque Inc., Kyoto, Japan) according to the manufacturer's instructions. Full-length DR5 cDNA was used as a probe for Northern blot analysis. Northern blot analysis and RNase protection assay were carried out as previously described (Nakata et al., 2004) .
Luciferase assay
HeLa cells (1 Â 10 5 cells) were seeded in six-well plates, and 1.0 mg of pDR5PF ( ¼ pDR5/SacI; Yoshida et al., 2001) or vacant vector plasmid was transfected using a CellPhect transfection kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). After 24 h of incubation, the cells were treated with or without luteolin, and 48 h after the transfection they were collected for luciferase assay. The luciferase assay was performed as previously described (Yoshida et al., 2001) . All luciferase assays were carried out in triplicate, and each assay was performed at least three times. The data were analyzed using the Student's t-test. Differences were considered to be statistically significant from the controls for Po0.05.
Western blot analysis
Western blot analysis was carried out as previously described (Nakata et al., 2004) . Rabbit polyclonal anti-DR5 antibody (Millennium Biotechnology, Ramona, CA, USA), rabbit polyclonal anti-DR4 antibody (ProSci, Poway, CA, USA), rabbit polyclonal anti-TRAIL antibody (Cayman Chemical, Ann Arbor, MI, USA), mouse monoclonal anti-Bid, anticaspase-8, -9, -10 antibodies (MBL, Nagoya, Japan), mouse monoclonal anti-pro-caspase-3 antibody (Immunotech, Marseille, France) and mouse monoclonal anti-b-actin (Sigma, St Louis, MO, USA) were used as primary antibodies. Signals were detected using an ECL or ECL Advance Western blot analysis system (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
siRNAs
The DR5 and LacZ siRNA sequences used were previously described (Wang and El-Deiry, 2004) , and DR4 siRNA sequences used were previously described (Ren et al., 2004) (synthesized by Proligo, Kyoto, Japan), where LacZ siRNA was used as a siRNA control. In brief, 1 day prior to transfection, cells were seeded without antibiotics to a density of 30-40%. DR5, DR4 and LacZ siRNA (1 nM in HeLa, 10 nM in DU145) were transfected into cells using a modified oligofectamine protocol (Invitrogen, Carlsbad, CA, USA), for which the volume of oligofectamine was reduced to one-third the recommended volume to limit toxic effects. After 24 h, the cells were treated with 20 mM luteolin for 24 h and then harvested.
Abbreviations DR5, death receptor 5; TNF, tumor necrosis factor; TNF-R, tumor necrosis factor-receptor; TRAIL, tumor necrosis factorrelated apoptosis-inducing ligand; Bid, Bcl-2-interacting domain; PBMC, peripheral blood mononuclear cells; GAPDH, glycelaldehyde-3-phosphate dehydrogenase. 
